Norfloxacin does not alter warfarin's disposition or anticoagulant effect.
Drug interactions related to inhibition of hepatic drug metabolism have been identified for some fluoroquinolone antibiotics. This study was designed to investigate whether the fluoroquinolone norfloxacin at the usual clinical dosage interacts with the anticoagulant agent warfarin. Ten healthy male subjects were administered a single oral dose of 30 mg warfarin sodium alone or during multiple-dose treatment with norfloxacin, 400 mg bid, in a randomized, crossover fashion. Plasma warfarin concentrations and prothrombin times were measured for 6 days after each of the two warfarin doses. The pharmacokinetic parameters of warfarin were comparable in the absence and presence of norfloxacin, including no significant differences in warfarin's elimination half-life, apparent total clearance, apparent volume of distribution, or peak plasma concentration. Norfloxacin also had no significant effect on the anticoagulant effect of warfarin, as assessed by the area under the prothrombin time versus time curve and the maximum response for prothrombin time. The lack of pharmacokinetic or pharmacodynamic interaction observed in this study suggests that a clinically important interaction of norfloxacin and warfarin is unlikely to occur in patients requiring both drugs.
Rocci
M L
ML
Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107-5563.
Vlasses
P H
PH
Distlerath
L M
LM
Gregg
M H
MH
Wheeler
S C
SC
Zing
W
W
Bjornsson
T D
TD
D000328:Adult; D004347:Drug Interactions; D006207:Half-Life; D006801:Humans; D008297:Male; D009643:Norfloxacin / Q000008:administration & dosage / Q000494:pharmacology*; D011517:Prothrombin Time; D011897:Random Allocation; D013997:Time Factors; D014859:Warfarin / Q000037:antagonists & inhibitors / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology
D014859:Warfarin; D009643:Norfloxacin